Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Apr 21:2:30.
doi: 10.21037/tgh.2017.03.18. eCollection 2017.

No benefit from ramucirumab in first-line chemotherapy?

Seiichiro Mitani  1 , Kei Muro  1
Affiliations
Editorial

No benefit from ramucirumab in first-line chemotherapy?

Seiichiro Mitani et al. Transl Gastroenterol Hepatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: K Muro has received research funding from MSD, Daiichi Sankyo, Ono, Kyowa Hakko Kirin, Shionogi, and Gilead Sciences; and he has also received honoraria for lectures from Chugai, Takeda, Eli Lilly, Merck Serono, Taiho, and Yakult honsha. S Mitani has no conflicts of interest to declare.

Comment on

References

    1. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-9. 10.1016/S0140-6736(13)61719-5 - DOI - PubMed
    1. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-35. 10.1016/S1470-2045(14)70420-6 - DOI - PubMed
    1. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665-73. 10.1016/S0140-6736(14)60845-X - DOI - PubMed
    1. Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16:499-508. 10.1016/S1470-2045(15)70127-0 - DOI - PubMed
    1. Yoon HH, Bendell JC, Braiteh FS, et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol 2016;27:2196-203. 10.1093/annonc/mdw423 - DOI - PMC - PubMed

LinkOut - more resources